Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04507126 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04507126: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04507126 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04507126, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
A pilot study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older adults.
Interventions
- BIOLOGICAL Bacillus Calmette-Guerin (BCG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2022-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04507126
The ClinicalTrials.gov registry entry for NCT04507126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bacillus Calmette-Guerin (BCG) is the first listed.
NCT04507126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04507126 about?
NCT04507126 is a clinical study titled "A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.". A pilot study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older adults.
What is the current status of trial NCT04507126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-03-01. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT04507126?
The interventions under investigation include: Bacillus Calmette-Guerin (BCG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04507126?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.